Tevogen Bio Signs LOI to Evaluate Apozeal Pharmaceutical Acquisition, Advancing Generics Strategy
TVGN is trading near its 52-week low of $0.143 (9.7% above the low).
Summary
Tevogen Bio Holdings Inc. has signed a Letter of Intent (LOI) to evaluate the potential acquisition of Apozeal Pharmaceutical, a move aimed at advancing its generics strategy. This development signals a new strategic direction for the micro-cap company, potentially diversifying its business into the generics market. The news follows a period of significant corporate actions, including a 1-for-50 reverse stock split effective March 6 and a substantial increase in authorized shares, as well as a separate LOI for a Contract Research Organization announced on February 27. While the LOI is non-binding, it indicates potential growth avenues and a proactive M&A approach. Traders will be watching for updates on the due diligence process and any definitive agreement.
At the time of this announcement, TVGN was trading at $0.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $31.6M. The 52-week trading range was $0.14 to $1.51. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.